The AIM-to-OBserve study: Adipokines and Inflammatory Markers in childhood OBesity

The AIM-to-OBserve study: Adipokines and Inflammatory Markers in childhood OBesity - AIMOB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33433

Enrollment

140

Registered

2009-10-23

Start date

2010-01-12

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adiposity Obesity

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Patientgroup: 6-16 years of age BMI (>30 kg/m2 projected at the age of18 years), according to international standards, see also Hirasing RA, Fredriks AM, van BS, Verloove-Vanhorick SP, Wit JM. [Increased prevalence of overweight and obesity in Dutch children, and the detection of overweight and obesity using international criteria and new reference diagrams]. Ned Tijdschr Geneeskd 2001 July 7;145(27):1303-8.;Controls: Sex and age matched to patient group -0.5 SD

Exclusion criteria

Exclusion criteria: Patientgroup: - Intoxication (smoking, i.e. sigaret use, drug-use) - Acute illness (fever) - Mental retardation - Allergy with positive RAST for food/inhalation allergy and (history of) Muller class I-II reaction (i.e. severe systemic allergy/anaphylaxis) - Asthma (based on doctors* diagnosis: history of recurrent wheezing, obstructive lung function tests with reversibility after administration of β2-sympathicomimetics, use of asthma-medication) Controls: - Intoxication (smoking, drug-use) - Acute illness (fever) - Mental retardation Exclusion criteria for involved referrals: - Allergy with positive RAST for food/inhalation allergy and (history of) Muller class I-II reaction (i.e. severe systemic allergy/anaphylaxis) - Asthma (based on doctors* diagnosis: history of recurrent wheezing, obstructive lung function tests with reversibility after administration of β2-sympathicomimetics, use of asthma-medication) - Complaints of fatigue/malaise explained by M.Pfeiffer, inflammatory or infectious illness (e.g. inflammatory bowel disease, (viral) hepatitis, rheumatologic disease) - Assessment of height when short or tall stature (height ± 1 SD of target height (TH), so height outside TH-range) or endocrine explanation for abnormal growth pattern (e.g. growth hormone deficiency) The exclusion-criteria are formulated on the assumption that these might influence adipokine/inflammatory profiles.

Design outcomes

Primary

Measure	Time frame
1) the difference in adipokine/inflammatory profiles between obese children and normal weight controls. 2) the relation between adipokine/inflammatory profiles and clinical parameters for obesity.	—

Countries

Netherlands

Outcome results